In this e-learning course, the role of novel diabetes treatment approaches in the prevention of CVD in patients with T2DM will be discussed. Member registration (free) is needed to enroll in this course.
Prof. Landmesser gives an introduction to the symposium about managing diabetes in CV risk reduction, that was held during the virtual ESC 2020 congress.
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.
Jorge Plutzky describes potential mechanisms for the benefit of some GLP1-RA in CVOTs and discusses their possible effects on atherosclerosis in patients with diabetes.
Prof. Landmesser discusses with professors Marx, Plutzky and Deanfield how to implement new therapies to reduce CV risk in patients with diabetes.
Prof. Marx discusses evidence on how CV risk in diabetes can be reduced by new diabetes agents and current guideline recommendations to manage patients with diabetes and high CV risk.
Expert discussion on expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes.